0001169245-22-000067.txt : 20220520
0001169245-22-000067.hdr.sgml : 20220520
20220520164713
ACCESSION NUMBER: 0001169245-22-000067
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210818
FILED AS OF DATE: 20220520
DATE AS OF CHANGE: 20220520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hutson Nancy J
CENTRAL INDEX KEY: 0001379222
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38697
FILM NUMBER: 22948349
MAIL ADDRESS:
STREET 1: 64 MONTAUK AVENUE
CITY: STONINGTON
STATE: CT
ZIP: 06378
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PhaseBio Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001169245
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030375697
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: (610) 981-6500
MAIL ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
FORMER COMPANY:
FORMER CONFORMED NAME: Phase Biosciences Inc
DATE OF NAME CHANGE: 20061013
FORMER COMPANY:
FORMER CONFORMED NAME: DT BIOSCIENCES INC
DATE OF NAME CHANGE: 20020315
4/A
1
wf-form4a_165307960124153.xml
FORM 4/A
X0306
4/A
2021-08-18
2021-08-19
0
0001169245
PhaseBio Pharmaceuticals Inc
PHAS
0001379222
Hutson Nancy J
C/O PHASEBIO PHARMACEUTICALS, INC.
1 GREAT VALLEY PARKWAY, SUITE 30
MALVERN
PA
19355
1
0
0
0
Common Stock
2021-08-18
4
P
0
3000
3.08
A
4000
I
Held in an individual retirement account for the benefit of the Reporting Person
Common Stock
33760
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.07 to $3.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
Amended to report direct share ownership.
/s/ John P. Sharp, Attorney-in-fact
2022-05-20